HHS plans new FDA deputy commissioner roles for technology and drugs, sources say
HHS plans to name two deputy commissioners for technology and drugs, said two sources familiar with the matter.
The US Department of Health and Human Services (HHS) is reportedly planning to create two new deputy commissioner roles at the Food and Drug Administration (FDA). According to sources, these roles will focus on technology and drugs, respectively. This development suggests that the FDA is looking to strengthen its capabilities in these areas, which could have significant implications for the industries it regulates.
The creation of these roles underscores the growing importance of technology and pharmaceuticals in the healthcare landscape. The FDA has been actively working to keep pace with rapid advancements in fields like digital health and gene therapy, and these new roles may help the agency better address these emerging trends. For brokers, this development could be relevant to companies in the healthcare and pharmaceutical sectors, which may be impacted by any changes in FDA oversight or policy.
Going forward, brokers should watch for further details on the qualifications and responsibilities of these new deputy commissioner roles, as well as any potential changes in FDA policy or guidance that may result from their establishment. Additionally, industry participants may want to monitor how these new roles affect the FDA's review and approval processes for technology and pharmaceutical products, and how this may impact the companies they cover.
Originally reported by cnbc.com. BrokerNews adds analysis for finance & markets readers.